Anteris Technologies Achieves Key Milestone in Cardiac Care

Anteris Technologies Global Corp. ( (AVR) ) has issued an announcement.

On March 31, 2025, Anteris Technologies Global Corp. announced a significant clinical milestone, having treated over 100 patients with its DurAVR® Transcatheter Heart Valve (THV). This achievement underscores the company’s commitment to revolutionizing cardiac care for patients with severe aortic stenosis. The milestone marks a pivotal moment for Anteris as it prepares to commence the DurAVR® THV Pivotal Trial in the third quarter of 2025, pending FDA approval. The company’s progress highlights the potential of the DurAVR® THV to redefine success in aortic stenosis treatment, offering exceptional hemodynamic performance and safety, with no valve or cardiovascular-related mortality reported at one year.

More about Anteris Technologies Global Corp.

Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. Based in Australia with a significant presence in Minneapolis, USA, the company specializes in treating structural heart disease, particularly aortic stenosis, with its lead product, the DurAVR® Transcatheter Heart Valve (THV).

YTD Price Performance: -31.53%

Average Trading Volume: 182,976

For detailed information about AVR stock, go to TipRanks’ Stock Analysis page.